Zydus gets USFDA's nod for Candesartan Cilexetil, Hydrochlorothiazide Tablets

29 Nov 2017 Evaluate

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Candesartan Cilexetil and Hydrochlorothiazide Tablets USP in the strengths of 16 mg/12.5 mg, 32 mg/12.5 mg and 32 mg/25 mg. The drug combines an angiotensin II receptor (type ATI) antagonist and a diuretic, hydrochlorothiazide and is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 175 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.


Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×